^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Osteosarcoma |
| Drug: | cisplatin (DNA synthesis inhibitor) + ifosfamide (Bifunctional alkylating agent) + pegylated liposomal doxorubicin (Topoisomerase II inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
Excerpt:
Summary of recommendations...Treatment (locoregional and advanced disease)...In patients aged > 40, preferred regimens often combine doxorubicin, cisplatin and ifosfamide without HD-MTX [III, B].
DOI:
10.1093/annonc/mdy310
